Director at OKYO Pharma (NASDAQ: OKYO) receives stock options on 6,500 shares

Rhea-AI Filing Summary

OKYO Pharma Ltd director Simon Willy Jules received a grant of options over 6,500 common shares at an exercise price of $1.85 per share. These options relate to common shares and increase his directly held derivative position to 135,502 options following the transaction. The options become exercisable on June 8, 2027 and are scheduled to expire on June 8, 2036, indicating a long-term, compensation-related award rather than an open-market share purchase or sale.

Insights

Equity compensation analyst

Director received a routine stock option grant with long-dated expiry.

Director Simon Willy Jules was granted options over 6,500 OKYO Pharma Ltd common shares at an exercise price of $1.85 per share. The Form 4 characterizes this as a grant or award, not an open-market trade.

After this grant, his total directly held derivative position rises to 135,502 options, with these specific options exercisable from June 8, 2027 until June 8, 2036. This structure is typical for long-term incentive compensation, aligning the director’s potential benefit with future share price performance.

Because this is a compensation-related award rather than a discretionary market purchase or sale, it carries weaker signaling value about the director’s short-term view on the stock. Subsequent company disclosures may provide more detail on the broader equity incentive program.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Simon Willy Jules

Role null

Type	Security	Shares	Price	Value
Grant/Award	Option	6,500	$1.85	$12K

Holdings After Transaction: Option — 135,502 shares (Direct, null)

Footnotes (1)

Key Figures

Options granted: 6,500 options Exercise price: $1.85 per share Total options after grant: 135,502 options +2 more

5 metrics

Options granted 6,500 options Grant to director on June 8, 2026

Exercise price $1.85 per share Strike price for granted options

Total options after grant 135,502 options Director’s derivative holdings following transaction

Option exercisability date June 8, 2027 Date options become exercisable

Option expiration date June 8, 2036 End of option term

Key Terms

Grant, award, or other acquisition, Option, Common Shares, exercise price, +1 more

5 terms

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

Option financial

"security_title: Option"

Common Shares financial

"underlying_security_title: Common Shares"

Common shares are the basic units of ownership in a company that give holders a claim on profits and a right to vote on key matters, like electing the board. Think of them as membership cards in a club: they let you share in successes and losses, but in a bankruptcy or liquidation they are paid after creditors and preferred shareholders, so their value can swing more and matters for assessing risk and potential return.

exercise price financial

"conversion_or_exercise_price: 1.8500"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: 2036-06-08T00:00:00.000Z"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Simon Willy Jules

(Last) (First) (Middle)

14-15 CONDUIT ST

(Street)

LONDON W1S 2XJ

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
OKYO Pharma Ltd [ OKYO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option	$1.85	06/08/2026	06/08/2026	A		6,500		06/08/2027	06/08/2036	Common Shares	6,500	$1.85	135,502	D

Explanation of Responses:

Remarks:

Options vest 25% per year over four years beginning on the first anniversary of the grant date

	/s/ Willy Simon	06/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did OKYO (OKYO) director Simon Willy Jules report in this Form 4?

Director Simon Willy Jules reported receiving a grant of options over 6,500 OKYO Pharma common shares. The options were awarded at an exercise price of $1.85 per share as a compensation-related grant, rather than an open-market purchase or sale of existing shares.

What is the exercise price and size of the OKYO (OKYO) option grant?

The grant consists of options over 6,500 common shares with an exercise price of $1.85 per share. This means the director can buy those shares at $1.85 if he exercises the options during the specified exercise period in the future.

When do Simon Willy Jules’s OKYO (OKYO) options vest and expire?

The options become exercisable on June 8, 2027 and expire on June 8, 2036. This long window gives the director several years to decide when to exercise, tying potential gains to the company’s share price performance over that period.

How many OKYO (OKYO) derivative securities does the director hold after this grant?

Following the grant, the director holds 135,502 derivative securities in total, all reported as directly owned. This figure represents his overall option position after adding the 6,500 newly awarded options disclosed in the Form 4 filing.

Is the OKYO (OKYO) Form 4 transaction an open-market buy or sell?

The Form 4 describes the transaction as a grant or award acquisition, coded as an "A" transaction. It is not an open-market buy or sell, but rather a compensation-related stock option grant provided by the company to the director.